

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/108706 A1

(51) International Patent Classification⁷: **C07D 403/12**,
A61K 31/506, A61P 25/18

(DE). **TESCHENDORF, Hans-Jürgen** [DE/DE];
Georg-Nuss-Str. 5, 67373 Dudenhofen (DE).

(21) International Application Number:
PCT/EP2004/006139

(74) Agent: **POHL, Michael**; Reitstötter, Kinzebach & Partner
(GbR), Ludwigsplatz 4, 67059 Ludwigshafen (DE).

(22) International Filing Date: 7 June 2004 (07.06.2004)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/455,514 5 June 2003 (05.06.2003) US

(71) Applicant (for all designated States except US): **ABBOTT
GMBH & CO. KG** [DE/DE]; Max-Planck-Ring 2, 65205
Wiesbaden (DE).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAUPT, Andreas**
[DE/DE]; Schaelzigweg 52, 68723 Schwetzingen (DE).
GRANDEL, Roland [DE/DE]; Birkenweg 49, 69221
Dossenheim (DE). **BRAJE, Wilfried** [DE/DE]; Unter
dem Hopfenberge 15, 31737 Rinteln (DE). **GENESTE,
Hervé** [FR/DE]; Rehbachstr. 42, 67141 Neuhofen
(DE). **DRESCHER, Karla** [DE/DE]; Unteres Bieth
10, 69221 Dossenheim (DE). **STARCK, Dorothea**
[DE/DE]; Kaiser-Wilhelm-Str. 31, 67059 Ludwigshafen

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF
THE DOPAMINE D₃ RECEPTOR

(57) Abstract: The invention relates to triazole compounds of the general formula I wherein R¹ is hydrogen or methyl, and R² is
C₃-C₄alkyl or C₁-C₂fluoroalkyl, as well as the physiologically tolerated acid addition salts of these compounds. The invention also
relates to a pharmaceutical composition that comprises at least one triazole compound of the formula (I) and/or at least one physi-
ologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine
D₃ receptor antagonists or dopamine D₃agonists, said method comprising administering an effective amount of at least one triazole
compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.



WO 2004/108706 A1

TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D₃ RECEPTOR

Background Of The Invention

5 The present invention relates to novel triazole compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D₃ receptor.

10 Neurons obtain their information by way of G protein-coupled receptors, *inter alia*. A large number of substances exert their effect by way of these receptors. One of them is dopamine. Confirmed findings exist with regard to the presence of dopamine and its physiological function as a neurotransmitter. Disorders in the dopaminergic transmitter system result in diseases of the central nervous system which include, for example, schizophrenia, depression and Parkinson's disease. These diseases, and others, are treated with drugs which interact with the dopamine receptors.


15 Up until 1990, two subtypes of dopamine receptor had been clearly defined pharmacologically, termed D₁ and D₂ receptors. More recently, a third subtype was found, namely, the D₃ receptor which appears to mediate some effects of antipsychotics and antiparkinsonians (J.C. Schwartz *et al.*, "The Dopamine D₃ Receptor as a Target for Antipsychotics" in Novel Antipsychotic Drugs, H.Y. Meltzer, ed., Raven Press, New York 1992, pages 135-144; M. Dooley *et al.*, *Drugs and Aging* 1998, 12:495-514; J.N. Joyce, 20 *Pharmacology and Therapeutics* 2001, 90:231-59, "The Dopamine D₃ Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs"). Since then, the dopamine receptors have been divided into two families. On the one hand, there is the D₂ group, consisting of D₂, D₃ and D₄ receptors, and, on the other hand, the D₁ group, consisting of D₁ and D₅ receptors.

25 Whereas D₁ and D₂ receptors are widely distributed, D₃ receptors appear to be expressed regioselectively. Thus, these receptors are preferentially to be found in the limbic system and the projection regions of the mesolimbic dopamine system, especially in the nucleus accumbens, but also in other regions, such as the amygdala. Because of this comparatively regioselective expression, D₃ receptors are regarded as being a target 30 having few side-effects and it is assumed that while a selective D₃ ligand would have the properties of known antipsychotics, it would not have their dopamine D₂ receptor-mediated neurological side-effects (P. Sokoloff *et al.*, *Arzneim. Forsch./Drug Res.* 42(1):224 (1992), "Localization and Function of the D₃ Dopamine Receptor"; P. Sokoloff *et al.*, *Nature*, 347:146 (1990), "Molecular Cloning and Characterization of a Novel Dopamine Receptor 35 (D₃) as a Target for Neuroleptics").

Triazole compounds having an affinity for the dopamine D₃ receptor have been described previously on various occasions, as for example in published PCT applications WO 96/02520, WO 99/02503, WO 00/42036, WO 00/42037, WO 00/42038. Some of these compounds possess high affinities for the dopamine D₃ receptor, and have therefore been proposed as being suitable for treating diseases of the central nervous system. Unfortunately, their selectivity towards the D₃ receptor is not always satisfactory. Moreover, it has often been difficult to achieve high brain levels with such known compounds.

Summary Of The Invention

It has now been found that certain triazole compounds exhibit, to a surprising and unexpected degree, highly selective binding to the dopamine D₃ receptor as well as the ability to attain high brain levels. Such compounds are those having the general formula I



wherein

R¹ is hydrogen or methyl and

R² is C₃-C₄ alkyl or C₁-C₂ fluoroalkyl,

and the physiologically tolerated acid addition salts of these compounds.

The present invention therefore relates to triazole compounds of the general formula I and to their physiologically tolerated acid addition salts.

The present invention also relates to a pharmaceutical composition which comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances.

The present invention also relates to a method for treating disorders which respond to influencing by dopamine D₃ receptor antagonists or dopamine D₃ agonists, said method comprising administering an effective amount of at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt of I to a subject in need thereof.

Detailed Description Of The Invention

The diseases which respond to the influence of dopamine D₃ receptor antagonists or agonists include disorders and diseases of the central nervous system, in particular affective disturbances, neurotic disturbances, stress disturbances and somatoform disturbances and psychoses, and especially schizophrenia, depression, bipolar disorder, substance abuse, dementia, major depressive disorder, anxiety, autism, attention deficit disorder with or without hyperactivity and personality disorder. In addition, D₃-mediated diseases may include disturbances of kidney function, in particular kidney function disturbances which are caused by diabetes mellitus (see WO 00/67847).

According to the invention, one or more compounds of the general formula I having the meanings mentioned at the outset can be used for treating the abovementioned indications. Provided the compounds of the formula I possess one or more centers of asymmetry, it is also possible to use enantiomeric mixtures, in particular racemates, diastereomeric mixtures and tautomeric mixtures; preferred, however, are the respective essentially pure enantiomers, diastereomers and tautomers.

It is likewise possible to use physiologically tolerated salts of the compounds of the formula I, especially acid addition salts with physiologically tolerated acids. Examples of suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, organic sulfonic acids having from 1 to 12 carbon atoms, e.g. C₁-C₄-alkylsulfonic acids such as methanesulfonic acid, cycloaliphatic sulfonic acids such as S-(+)-10-camphorsulfonic acids and aromatic sulfonic acids such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having from 2 to 10 carbon atoms such as oxalic acid, malonic acid, maleic acid, fumaric acid, mucic acid, lactic acid, tartaric acid, citric acid, glycolic acid and adipic acid, as well as *cis*- and *trans*-cinnamic acid, furoic acid and benzoic acid. Other utilizable acids are described in Fortschritte der Arzneimittelforschung [Advances in Drug Research], Volume 10, pages 224 ff., Birkhäuser Verlag, Basel and Stuttgart, 1966. The physiologically tolerated salts of compounds of the formula I may be present as the mono-, bis-, tris- and tetrakis-salts, that is, they may contain 1, 2, 3 or 4 of the aforementioned acid molecules per molecule of formula I. The acid molecules may be present in their acidic form or as an anion.

As used herein, C₃-C₄ alkyl is a straight-chain or branched alkyl group having 3 or 4 carbon atoms. Examples of such a group are *n*-propyl, isopropyl, *n*-butyl, 2-butyl, isobutyl and *tert*-butyl.

As used herein, C₁-C₂ fluoroalkyl is an alkyl group having 1 or 2 carbon atoms in which all or some (for example 1, 2, 3 or 4) of the hydrogen atoms are replaced by fluorine atoms. Examples include CF₃, CHF₂, CH₂F and CH₂CF₃.

With regard to using the compounds according to the invention as dopamine D₃ receptor ligands, preference is given to those compounds of formula I in which the radical R² is *n*-propyl, isopropyl or *tert*-butyl, or alternatively trifluoromethyl or difluoromethyl. More preferable are compounds in which R² is *tert*-butyl, difluoromethyl or trifluoromethyl, and most preferred are those in which R² is *tert*-butyl.

In a first embodiment of the invention R¹ is methyl and R² has the meanings given above, especially those which are given as preferred. Examples of preferred compounds of this embodiment are:

2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-*tert*-butyl-pyrimidine,
2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-propyl-pyrimidine, and
2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine,
2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine,

and the physiologically tolerated acid addition salts thereof, as for example hydrochlorides such as monohydrochlorides, bishydrochlorides, trishydrochlorides, mono- and dihydrogenphosphates, mono, bis-, tris- and tetraphosphates, citrates, sulfates, mono-, bis- and tris-nitrates, *trans*-cinnamates, mono- and bis-malonates, mono- and bis-maleates, galactarates, furoates, mono- and bis-mesylates, mono- and bis-oxalates, mono- and bis-benzenesulfonates, mono- and bis-tosylates, mono- and bis-S-(+)-10-campher sulfonates, glycolates and fumarates.

In another embodiment of the invention R¹ in formula I is hydrogen and R² has the meanings given above, especially those which are given as preferred. Examples of preferred compounds of this embodiment are:

2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-*tert*-butyl-pyrimidine,
2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-propyl-pyrimidine,
2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine,
2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine,

and the physiologically tolerated acid addition salts thereof, as for example hydrochlorides such as monohydrochlorides, bishydrochlorides, trishydrochlorides, mono- and

5 dihydrogenphosphates, mono, bis-, tris- and tetraphosphates, citrates, sulfates, mono-, bis- and tris-nitrates, *trans*-cinnamates, mono- and bis-malonates, mono- and bis-maleates, galactarates, furoates, mono- and bis-mesylates, mono- and bis-oxalates, mono- and bis-benzenesulfonates, mono- and bis-tosylates, mono- and bis-S-(+)-10-campher sulfonates, glycolates and fumarates.

Amongst the compounds of formula I the following compounds are especially preferred:

2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-*tert*-butyl-pyrimidine,

10 2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-*tert*-butyl-pyrimidine,

2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine,

2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine,


15 2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine,

2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine,

20 and the physiologically tolerated acid addition salts thereof, as described above. Most preferred among these is the first named compound, namely 2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-*tert*-butyl-pyrimidine and the physiologically tolerated acid addition salts thereof, as described above.

25 The compounds of the formula I can be prepared in analogy to methods which are well known in the art, as for example from the international patent applications cited in the introductory part. Preferred methods are outlined in schemes i) and ii) below:


Scheme i)



30 According to this scheme, a triazole of the formula II is reacted with a piperazinyldimethylpyrimidine compound of the formula III, wherein R^x is SH and Y is a conventional leaving group such as halogen such as chlorine, bromine or iodine, alkylsulfonyloxy such as

methanesulfonyloxy, arylsulfonyloxy such as phenylsulfonyloxy, or tolylsulfonyloxy (tosylate). The reaction can be performed using the conditions as described herein or in the prior art cited in the introductory part. R^x may also be chlorine or bromine, while Y is SH; in this case, the reaction can be performed using the reaction conditions as described by Hester, Jackson B., Jr. and Von Voigtlander, Philip, *Journal of Medicinal Chemistry* (1979), 22(11).

Scheme ii)




According to this scheme, a triazole of the formula IV is reacted with a piperazinyipyrimidine compound of the formula V, wherein Y is a conventional leaving group such as halogen, alkylsulfonyloxy, arylsulfonyloxy, etc as described above.

The compounds of the formulae II and IV are known in the art or can be prepared according to methods described in the literature, as for example in Houben Weyl „Handbuch der Organischen Chemie“, 4th Ed., Thieme Verlag, Stuttgart 1994, Volume E8/d, pages 479 et sequ.; in S. Kubota *et al.*, *Chem. Pharm. Bull* 1975, 23:955, or in A.R. Katritzky, C.W. Rees (ed.), "Comprehensive Heterocyclic Chemistry", 1st Ed. Pergamon Press 1984, in particular Vol. 5, part 4a, pages 733 et seq. and literature cited therein; or "The Chemistry of Heterocyclic Compounds" J. Wiley & Sons Inc. NY and literature cited therein. The compounds of the formulae III and V can be prepared according to routine methods as described for example in J.A. Kiristy *et al.*, *J. Med. Chem.*, 21:1303 or C.B. Pollard, *J. Am. Chem. Soc.* 1934, 56:2199.

Compounds of the formula II wherein R^x is chlorine or bromine can also be prepared from compounds II with R^x being OH according to the methods described by P. Viallefont *et al.* in *Bulletin de la Société Chimique de France* 1975, no. 3-4, 647-653, or by G. Maury *et al.* in *J. Heterocyclic Chemistry* 1977, 14:1311.

A preferred route to compounds of the formula III is shown in scheme iii below:


Scheme iii)



In a first step, a piperazine compound VI wherein Q is H or an protecting group for secondary amines is reacted with a pyrimidine compound VII wherein Z is halogen to yield a compound of the formula V. This compound is then reacted with a bifunctional propane compound Y-(CH₂)₃-Y', wherein Y and Y' are leaving groups of different reactivities which can be replaced by nucleophiles e.g. Y = Cl and Y' = Br. This method is known from the prior art cited in the introductory part of the application and also from WO 99/09015 and WO 03/002543. Compounds of the formula III wherein Y is OH may also be prepared by the method disclosed in WO 03/002543.

A simple method of producing the compounds of formula I comprises the reaction of a carboxylic acid of the formula R¹-COOH with 4-methyl-3-thiosemicarbazide in the presence of 1,1'-carbonyldiimidazole as shown in scheme iv).


Scheme iv)



The reaction can be performed using the conditions as described herein and in El-Deen, I. M. and Ibrahim, H. K., Phosphorus, Sulfur and Silicon and the Related Elements (2002), 177(3):733-740; Faidallah *et al.*, Phosphorus, Sulfur and Silicon and the Related Elements (2002), 177(1):67-79; Tumkevicius, Sigita and Vainilavicius, Povilas, *Journal of Chemical Research, Synopses* (2002), 5:213-215; Palaska *et al.*, *FABAD Journal of Pharmaceutical Sciences* (2001), 26(3):113-117; Li, Xin Zhi and Si, Zong Xing, *Chinese Chemical Letters* (2002), 13(2):129-132; and Suni *et al.*, *Tetrahedron* (2001), 57(10):2003-2009.

The preparation of the pyrimidine compounds VII is simply achieved by reacting *tert*-butylamidinium chloride with a suitable β-ketoester VIII to yield a 2-*tert*-butyl-

4-hydroxypyrimidine of the formula IX which can be transformed to the halo compound VII by reacting it with halogenating agent such as thionyl chloride, phosphoryl chloride, phosphoryl bromide, phosphorous trichloride, phosphorous tribromide or phosphorous pentachloride (see scheme v):



β -Ketoesters VIII where R^2 is alkyl such as propyl, isopropyl, or *tert*-butyl, or trifluoromethyl are commercially available and can directly be reacted with *tert*-butyl-amidinium chloride, which is also commercially available from e.g. Maybridge Ltd.

10 β -Ketoesters where R^2 is fluoroalkyl such as difluoromethyl can be simply synthesized according to the methods described in this application from the corresponding acid chlorides R^2-COCl by reaction with meldrum's acid (2,2-dimethyl-4,6-dioxo-1,3-dioxan) according to the process as described herein and in B. Trost *et al.*, *Journal of the American Chemical Society* (2002), 124(35):10396-10415; Paknikar, S. K. *et al.*, *Journal of the Indian Institute of Science* (2001), 81(2):175-179; and Brummell, David G. *et al.*,
15 *Journal of Medicinal Chemistry* (2001), 44(1):78-93.

If not otherwise indicated, the above-described reactions are generally carried out in a solvent at temperatures between room temperature and the boiling temperature of the solvent employed. Alternatively, the activation energy which is required for the reaction can be introduced into the reaction mixture using microwaves, something which has
20 proved to be of value, in particular, in the case of the reactions catalyzed by transition metals (with regard to reactions using microwaves, see *Tetrahedron* 2001, 57, p. 9199 ff. p. 9225 ff. and also, in a general manner, "Microwaves in Organic Synthesis", André Loupy (Ed.), Wiley-VCH 2002.

25 Examples of solvents which can be used are ethers such as diethyl ether, diisopropyl ether, methyl *tert*-butyl ether or tetrahydrofuran, aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, dimethoxyethane and acetonitrile, aromatic hydrocarbons such as toluene and xylene, ketones such as acetone or methyl ethyl ketone, halohydrocarbons such as dichloromethane, trichloromethane and dichloroethane, esters such as ethyl acetate and methyl butyrate, carboxylic acids such as acetic acid or
30 propionic acid, and alcohols such as methanol, ethanol, *n*-propanol, isopropanol and butanol.

If desired, it is possible for a base to be present in order to neutralize protons which are released in the reactions. Suitable bases include inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, alkoxides such as sodium methoxide or sodium ethoxide, alkali metal hydrides such as sodium hydride, organometallic compounds such as butyllithium compounds or alkylmagnesium compounds, and organic nitrogen bases such as triethylamine or pyridine. The latter compounds can at the same time serve as solvents.

The crude product is isolated in a customary manner, as for example by filtering, distilling off the solvent or extracting from the reaction mixture, *etc.* The resulting compounds can be purified in a customary manner, as for example by means of recrystallizing from a solvent, by means of chromatography or by means of converting into an acid addition salt.

The acid addition salts are prepared in a customary manner by mixing the free base with a corresponding acid, where appropriate in solution in an organic solvent as for example a lower alcohol such as methanol, ethanol, *n*-propanol or isopropanol, an ether such as methyl *tert*-butyl ether or diisopropyl ether, a ketone such as acetone or methyl ethyl ketone, or an ester such as ethyl acetate. For example, the free base of formula I and suitable amounts of the corresponding acid, such as from 1 to 4 moles per mol of formula I, are dissolved in a suitable solvent, preferably in a lower alcohol such as methanol, ethanol, *n*-propanol or isopropanol. Heating may be applied to dissolve the solids, if necessary. Solvents, wherein the acid addition salt of I is insoluble (anti-solvents), might be added to precipitate the salt. Suitable anti-solvents comprise C₁-C₄-alkylesters of C₁-C₄-aliphatic acids such as ethyl acetate, aliphatic and cycloaliphatic hydrocarbons such as hexane, cyclohexane, heptane, *etc.*, di-C₁-C₄-alkylethers such as methyl *tert*-butyl ether or diisopropyl ether. A part or all of the anti-solvent may be added to the hot solution of the salt and the thus obtained solution is cooled; the remainder of the anti-solvent is then added until the concentration of the salt in the mother liquor is as low as approximately 10 mg/l or lower.

The compounds according to the invention of the formula I are surprisingly highly selective dopamine D₃ receptor ligands. Because of their low affinity for other receptors such as D₁ receptors, D₄ receptors, α 1-adrenergic and/or α 2-adrenergic receptors, muscarinic receptors, histamine receptors, opiate receptors and, in particular, dopamine D₂ receptors, the compounds can be expected to give rise to fewer side-effects than do the classic neuroleptics, which are D₂ receptor antagonists.

The high affinity of the compounds according to the invention for D₃ receptors is reflected in very low in-vitro K_i values of as a rule less than 50 nM (nmol/l), preferably of less than 10 nM and, in particular of less than 5 nM. The displacement of [¹²⁵I]-iodosulpride can, for example, be used in receptor binding studies for determining binding affinities for D₃ receptors.

The selectivity of the compounds of the invention for the D₂ receptor relative to the D₃ receptor, expressed as $K_i(D_2)/K_i(D_3)$, is as a rule at least 50, preferably at least 100, more preferably at least 150, and most advantageously more than 200. The displacement of [³H]SCH23390, [¹²⁵I] iodosulpride or [¹²⁵I] spiperone can be used, for example, in carrying out receptor binding studies on D₁, D₂ and D₄ receptors.

Because of their binding profile, the compounds can be used for treating diseases which respond to dopamine D₃ ligands, that is, they can be expected to be effective for treating those medical disorders or diseases in which exerting an influence on (modulating) the dopamine D₃ receptors leads to an improvement in the clinical picture or to the disease being cured. Examples of these diseases are disorders or diseases of the central nervous system.

Disorders or diseases of the central nervous system are understood as meaning disorders which affect the spinal chord and, in particular, the brain. Within the meaning of the invention, the term "disorders" denotes disturbances and/or anomalies which are as a rule regarded as being pathological conditions or functions and which can manifest themselves in the form of particular signs, symptoms and/or malfunctions. While the treatment according to the invention can be directed toward individual disorders, that is, anomalies or pathological conditions, it is also possible for several anomalies, which may be causatively linked to each other, to be combined into patterns or syndromes which can be treated in accordance with the invention.

The disorders which can be treated in accordance with the invention are, in particular, psychiatric and neurological disturbances. These disturbances include, in particular, organic disturbances, including symptomatic disturbances such as psychoses of the acute exogenous reaction type or attendant psychoses of organic or exogenous cause as for example in association with metabolic disturbances, infections and endocrinopathologies; endogenous psychoses such as schizophrenia and schizotypal and delusional disturbances; affective disturbances such as depressions, major depressive disorder, mania and/or manic-depressive conditions; mixed forms of the above-described disturbances; neurotic and somatoform disturbances and also disturbances in association with stress; dissociative disturbances such as loss of consciousness, clouding of consciousness, double consciousness and personality disturbances; autism; disturbances in attention and waking/sleeping behavior such as behavioral disturbances and emotional disturbances whose onset lies in childhood and youth as for example hyperactivity in children, intellectual deficits such as attention disturbances (attention deficit disorders with or without hyperactivity), memory disturbances and cognitive disturbances such as impaired learning and memory (impaired cognitive function), dementia, narcolepsy and sleep disturbances such as restless legs syndrome; development disturbances; anxiety states; delirium; sexual disturbances such as impotence in men; eating disturbances such

as anorexia or bulimia; addiction; bipolar disorder; and other unspecified psychiatric disturbances.

The disorders which can be treated in accordance with the invention also include Parkinson's disease and epilepsy and, in particular, the affective disturbances connected thereto.

Also treatable are addictive diseases (substance abuse), that is, psychic disorders and behavioral disturbances which are caused by the abuse of psychotropic substances such as pharmaceuticals or narcotics, and also other addiction behaviors such as addiction to gaming and/or impulse control disorders not elsewhere classified. Examples of addictive substances include opioids such as morphine, heroin and codeine; cocaine; nicotine; alcohol; substances which interact with the GABA chloride channel complex; sedatives, hypnotics and tranquilizers as for example benzodiazepines; LSD; cannabinoids; psychomotor stimulants such as 3,4-methylenedioxy-N-methylamphetamine (ecstasy); amphetamine and amphetamine-like substances such as methylphenidate; and other stimulants including caffeine. Addictive substances which come particularly into consideration are opioids, cocaine, amphetamine or amphetamine-like substances, nicotine and alcohol.

With regard to the treatment of addiction diseases, particular preference is given to those compounds according to the invention of the formula I which themselves do not possess any psychotropic effect. This can also be observed in a test using rats, which, after having been administered compounds which can be used in accordance with the invention, reduce their self administration of psychotropic substances, for example cocaine.

According to another aspect of the present invention, the compounds according to the invention are suitable for treating disorders whose causes can at least partially be attributed to an anomalous activity of dopamine D₃ receptors.

According to another aspect of the present invention, the treatment is directed, in particular, toward those disorders which can be influenced, within the sense of an expedient medicinal treatment, by the binding of preferably exogenously administered binding partners (ligands) to dopamine D₃ receptors.

The diseases which can be treated with the compounds according to the invention are frequently characterized by progressive development, that is, the above-described conditions change over the course of time; as a rule, the severity increases and conditions may possibly merge into each other or other conditions may appear in addition to those which already exist.

The compounds according to the invention can be used to treat a large number of signs, symptoms and/or malfunctions which are connected with the disorders of the central

nervous system and, in particular, the abovementioned conditions. These signs, symptoms and/or malfunctions include, for example, a disturbed relationship to reality, lack of insight and ability to meet customary social norms or the demands made by life, changes in temperament, changes in individual drives, such as hunger, sleep, thirst, etc., and in mood, disturbances in the ability to observe and combine, changes in personality, in particular emotional lability, hallucinations, ego-disturbances, distractedness, ambivalence, autism, depersonalization and false perceptions, delusional ideas, chanting speech, lack of synkinesia, short-step gait, flexed posture of trunk and limbs, tremor, poverty of facial expression, monotonous speech, depressions, apathy, impeded spontaneity and decisiveness, impoverished association ability, anxiety, nervous agitation, stammering, social phobia, panic disturbances, withdrawal symptoms in association with dependency, manifold syndromes, states of excitation and confusion, dysphoria, dyskinetic syndromes and tic disorders, such as Huntington's chorea and Gilles-de-la-Tourette's syndrome, vertigo syndromes such as peripheral positional, rotational and oscillatory vertigo, melancholia, hysteria, hypochondria and the like.

Within the meaning of the invention, a treatment also includes a preventive treatment (prophylaxis), in particular as relapse prophylaxis or phase prophylaxis, as well as the treatment of acute or chronic signs, symptoms and/or malfunctions. The treatment can be orientated symptomatically, as for example for the suppression of symptoms. It can be effected over a short period, be orientated over the medium term or can be a long-term treatment, as for example within the context of a maintenance therapy.

Surprisingly, high brain levels in excess of 100 or even of 200 ng/g or even of 500 ng/g (determined in rats as the value C_{max}) can be achieved when administering the compounds of the invention.

Therefore the compounds according to the invention are preferentially suitable for treating diseases of the central nervous system, in particular for treating affective disorders; neurotic disturbances, stress disturbances and somatoform disturbances and psychoses, and, in particular, for treating schizophrenia and depression. Because of their high selectivity with regard to the D_3 receptor, the compounds I according to the invention are also suitable for treating disturbances of kidney function, in particular disturbances of kidney function which are caused by diabetes mellitus (see WO 00/67847) and, especially, diabetic nephropathy.

In addition, compounds of the present invention may possess other pharmacological and/or toxicological properties that render them especially suitable for development as pharmaceuticals. As an example, compounds of formula I having a low affinity for the HERG receptor could be expected to have a reduced likelihood of inducing QT-prolongation (regarded as a one predictor of risk of causing cardiac arrhythmia. (For a discussion of QT-prolongation see for example A. Cavalli *et al.*, *J. Med. Chem.* 2002,

45:3844-3853 and the literature cited therein; a HERG assay is commercially available from GENION Forschungsgesellschaft mbH, Hamburg, Germany).

5 Within the context of the treatment, the use according to the invention of the described compounds involves a method. In this method, an effective quantity of one or more compounds, as a rule formulated in accordance with pharmaceutical and veterinary practice, is administered to the individual to be treated, preferably a mammal, in particular a human being, productive animal or domestic animal. Whether such a treatment is indicated, and in which form it is to take place, depends on the individual case and is subject to medical assessment (diagnosis) which takes into consideration signs, symptoms and/or malfunctions which are present, the risks of developing particular signs, symptoms and/or malfunctions, and other factors.

10 As a rule, the treatment is effected by means of single or repeated daily administration, where appropriate together, or alternating, with other active compounds or active compound-containing preparations such that a daily dose of preferably from about 0.01 to 1000 mg/kg, more preferably from 0.1 to 1000 mg/kg of bodyweight in the case of oral administration, or of from about 0.01 to 100 mg/kg, more preferably from 0.1 to 100 mg/kg of bodyweight in the case of parenteral administration, is supplied to an individual to be treated.

15 The invention also relates to the production of pharmaceutical compositions for treating an individual, preferably a mammal and in particular a human being, a farm animal or a domestic animal. Thus, the compounds are customarily administered in the form of pharmaceutical compositions which comprise a pharmaceutically acceptable excipient together with at least one compound according to the invention and, where appropriate, other active compounds. These compositions can, for example, be administered orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly or intranasally.

20 Examples of suitable pharmaceutical formulations are solid medicinal forms such as powders, granules, tablets (in particular film tablets), lozenges, sachets, cachets, sugar-coated tablets, capsules such as hard gelatin capsules and soft gelatin capsules; suppositories or vaginal medicinal forms; semisolid medicinal forms such as ointments, creams, hydrogels, pastes or plasters; and also liquid medicinal forms such as solutions, emulsions (in particular oil-in-water emulsions), suspensions such as lotions, injection preparations and infusion preparations, and eyedrops and eardrops. Implanted release devices can also be used for administering inhibitors according to the invention. In addition, it is also possible to use liposomes or microspheres.

25 30 35 When producing the compositions, the compounds according to the invention are usually mixed or diluted with an excipient. Excipients can be solid, semisolid or liquid materials which serve as vehicles, carriers or medium for the active compound.

Suitable excipients are listed in the specialist medicinal monographs. In addition, the formulations can comprise pharmaceutically acceptable carriers or customary auxiliary substances, such as glidants; wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirritants; chelating agents; coating auxiliaries; emulsion stabilizers; film formers; gel formers; odor masking agents; taste corrigents; resin; hydrocolloids; solvents; solubilizers; neutralizing agents; diffusion accelerators; pigments; quaternary ammonium compounds; refatting and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; spreading auxiliaries; stabilizers; sterilants; suppository bases; tablet auxiliaries, such as binders, fillers, glidants, disintegrants or coatings; propellants; drying agents; opacifiers; thickeners; waxes; plasticizers and white mineral oils. A formulation in this regard is based on specialist knowledge as described, for example, in Fiedler, H.P., Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete [Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields], 4th edition, Aulendorf: ECV-Editio-Kantor-Verlag, 1996.

The following examples serve to explain the invention without limiting it.

The compounds were either characterized via proton-NMR in d₆-dimethylsulfoxid or d-chloroform on a 400 MHz or 500 MHz NMR instrument (Bruker AVANCE), or by mass spectrometry, generally recorded via HPLC-MS in a fast gradient on C18-material (electrospray-ionisation (ESI) mode), or melting point.

The magnetic nuclear resonance spectral properties (NMR) refer to the chemical shifts (δ) expressed in parts per million (ppm). The relative area of the shifts in the ¹H NMR spectrum corresponds to the number of hydrogen atoms for a particular functional type in the molecule. The nature of the shift, as regards multiplicity, is indicated as singlet (s), broad singlet (s. br.), doublet (d), broad doublet (d br.), triplet (t), broad triplet (t br.), quartet (q), quintet (quint.) and multiplet (m).

Preparation Examples:

I. Intermediates:

a. Synthesis of 3-mercapto-4-methyl-triazoles

a.1 4-Methyl-5-methyl-4H-[1,2,4]triazole-3-thiol

62.4 g of N,N'-carbonyldiimidazol (0.385 mol) were added in portions within 10 min. to a mixture of 22 g of acetic acid (0.366 mol) and 300 ml of dimethylformamide. The temperature rose from 22°C to about 26°C. After the addition was completed, stirring was continued for 30 min. Then 38.5 g of 4-methyl-3-thiosemicarbazid (0.366 mol) and 100 ml pyridine were added. The reaction mixture was heated to 100°C and stirred for 4 h at this temperature. Stirring was continued for 14 h at room

temperature. The solvent was evaporated under reduced pressure. The residue was treated with 200 ml of isopropanol and 150 ml of ethyl acetate, and re-dissolved at 80°C. Crystallization of the product started during cooling to room temperature. 300 ml of isopropanol were added and the obtained suspension was stirred for 1 h at room temperature. The precipitate was collected by filtration, washed twice with 75 ml of isopropanol each and dried under vacuum at 40°C to yield 20.4 g of the title compound.

MS (ESI) m/z : 130.1 $[M+H]^+$

$^1\text{H-NMR}$ (DMSO): δ [ppm] 13.4 (s, broad, 1H), 3.4 (s, 3H), 2.3 (s, 3H)

10 a.2 4-Methyl-4H-[1,2,4]triazole-3-thiol was purchased from Aldrich.

b. Preparation of 2-*tert*-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-pyrimidines

b.1 2-*tert*-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-methyl-pyrimidine

2-*tert*-butyl-4-hydroxy-6-*tert*.-butyl-pyrimidine

15 3 g of *tert*-butyl amidinium chloride (Maybridge) (31.7 mmol) were dissolved in 50 ml of ethanol. 12.7 ml of sodium methanolate (30 % in methanol) were added at room temperature. After 15 min., 4.82 g of methyl 4,4-difluoro-3-oxo butanoate (31.7 mmol) were added and the mixture was stirred at 78 °C for 4 h and 14 h at room temperature. The solvent was evaporated. 150 ml of water were added, and the pH adjusted to 6-7 by addition of 2N HCl. The precipitate was filtered, washed with water and dried in an oven under vacuum. Yield: 2.3 g

20 MS (ESI) m/z : 203.1 $[M+H]^+$

2-*tert*-butyl-4-chloro-6-difluoromethyl-pyrimidine

25 2.8 g of 2-*tert*-butyl-4-hydroxy-6-difluoromethyl-pyrimidine (13.9 mmol) and 3 ml of thionylchloride were stirred 14 h at room temperature and an additional 3 h at 76°C. 20 ml of dichloromethane were added with cooling, followed by addition of 15 ml of a saturated aqueous solution of sodium bicarbonate. The organic layer was separated, dried over magnesium sulfate and the solvent was evaporated to yield the crude title compound which was purified by column chromatography on silica gel (dichloromethane/hexane 1:1) to yield 0.8 g of product.

30 2-*tert*-butyl-4-(piperazin-1-yl)-6-difluoromethyl-pyrimidine

6.3 g of piperazine (73.5 mmol) were dissolved in 50 ml of ethanol. 2.31 g of 2-*tert*-butyl-4-chloro-6-difluoromethyl-pyrimidine (10.5 mmol) were added and the mixture

was stirred for 3 h at 78°C. The solvent was evaporated and the residue was added slowly to 100 ml of water. After cooling, the pH was adjusted to 12 with 2 N aqueous sodium hydroxide, and aqueous layer was extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and the solvent was evaporated to yield 2.34 g of the title compound.

MS (ESI) m/z: 271.1 [M+H]⁺

2-tert-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-trifluoromethyl-pyrimidine

A mixture of 1.03 g of 2-tert-butyl-4-piperazin-1-yl-6-methyl-pyrimidine (3.8 mmol), 0.5 ml of 1-bromo-3-chloropropane (4.9 mmol) and 1.7 ml of triethylamine (6.1 mmol) in 20 ml tetrahydrofuran were heated to reflux for 5 h, whereby a precipitate formed. The precipitate was filtered off and the remaining filtrate evaporated to dryness to yield the desired product.

MS (ESI) m/z: 347.1 [M+H]⁺

b.2 2-tert-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-tert-butyl-pyrimidine

40 g of 2-tert-butyl-4-[piperazin-1-yl]-6-tert-butyl-pyrimidine and 45.6 g of 1-bromo-3-chloro-propane were dissolved in 160 ml toluene. 13.3 g of 50 % aqueous sodium hydroxide and 2.3 g of tetrabutylammonium bromide (dissolved in 40 ml water) were added. The mixture was kept at 50 °C for 5 h under vigorous stirring. The reaction mixture was then extracted with water and ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and the solvent was evaporated. The product was purified by chromatography on silicagel (cyclohexane/0-10% ethyl acetate) to yield the title compound in 82 % yield.

MS (ESI) m/z: 353.3 [M+H]⁺

b.3 2-tert-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-propyl-pyrimidine

15 g of 2-tert-butyl-4-piperazin-1-yl-6-propyl-pyrimidine (57.2 mmol), 9 g of 1-bromo-3-chloropropane (57.2 mmol), 8.7 g of triethylamine (86.2 mmol) in 200 ml of acetonitrile were heated to reflux for 3 h. The precipitate was filtered off and the remaining filtrate evaporated to dryness. The thus obtained crude product was purified by chromatography on silica gel with dichloromethane/methanol (0-5 %). Yield: 6g (31 %).

MS (ESI) m/z: 339.2 [M+H]⁺

II. Preparation of the compounds I

EXAMPLE 1:

2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-tert-butyl-pyrimidine hydrochloride

- 5 1 g of 2-tert-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-tert-butyl-pyrimidine (2.83 mmol), 0.4 g of 4-Methyl-5-methyl-4H-[1,2,4]triazole-3-thiol (3.09 mmol), 0.2 g of lithium-hydroxide (8.35 mmol) and a spatula tip of potassium iodide were stirred in 20 ml of dimethylformamide for 2 h at 80°C. After addition of water and ethyl acetate, the organic phase was separated and dried over magnesium sulfate. After filtration and evaporation of the solvent, the crude product was purified by column chromatography on silica gel using dichloromethane-methanol (1-6%). Fractions containing the product were combined and the solvent was evaporated. The residue was dissolved in isopropanol, and a solution of HCl in isopropanol was added. On addition of diisopropylethylether, the product formed an oily mass. The solvent was decanted and the remaining oil evaporated to dryness to yield 15 0.6 g (41 %) of the title compound as a white solid.

MS (ESI) m/z: 446.3 [M+H]⁺

¹H-NMR (DMSO): δ [ppm] 12.0 (s, 1H, broad), 6.8 (s, 1H, broad), 4.7 (m, 2H, broad), 3.4-3.7 (m, 4H, very broad), 3.6 (s, 3H), 3.4 (m, 2H), 3.25 (m, 2H), 3.0-3.4 (m, 2H, very broad), 2.6 (s, 3H), 2.2 (m, 2H), 1.4 (s, 18H, broad)

20 EXAMPLE 2:

2-tert-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-tert-butyl-pyrimidine hydrochloride

- 25 1 g of 2-tert-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-tert-butyl-pyrimidine (2.83 mmol), 0.35 g of 4-Methyl-4H-[1,2,4]triazole-3-thiol (3.04 mmol), 0.2 g of lithium-hydroxide (8.35 mmol) and a spatula tip of potassium iodide were stirred for 72 h in 20 ml of dimethylformamide. Water and ethyl acetate were added and the organic layer was separated, dried over magnesium sulfate, filtered and the solvent was evaporated. The residue was subjected to a column chromatography on silica gel using dichloromethane-methanol (2-10%). Fractions containing the product were combined, the solvent was evaporated and the residue re-dissolved in isopropanol. The solution was treated with HCl/isopropanol. Diisopropylethylether was added whereby an oily precipitate formed. The solvent was decanted and the remaining oil evaporated to dryness to yield 30 1.1 g (77 %) of the title compound as a white solid.

MS (ESI) m/z: 432.2 [M+H]⁺

¹H-NMR (DMSO): δ [ppm] 12.5 (s, 1H, broad), 12.1 (s, 1H, broad), 9.65 (s, 1H), 6.85 (s, 1H), 5.0 (m, broad, 1H), 4.7 (m, broad, 1H), 3.75 (m, 1H), 3.7 (s, 3H), 3.65 (m, broad, 3H), 3.45 (m, 2H), 3.25 (m, 2H), 3.2 (m, 2H), 2.2 (m, 2H), 1.45 (m, 18H).

EXAMPLE 3:

5 2-tert-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-propyl-pyrimidine fumarate

Reaction of 1 g of 2-tert-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-propyl-pyrimidine (2.95 mmol) with 0.37 g of 4-methyl-4H-[1,2,4]triazole-3-thiol (3.21 mmol) yielded 0.33 g (21 %) of the title compound as a solid.

10 MS (ESI) m/z: 418.1 [M+H]⁺

¹H-NMR (DMSO): δ [ppm] 8.6 (s, 1H), 6.65 (s, 2H, fumarate), 6.45 (s, 1H), 3.65 (m, 4H), 3.6 (s, 3H), 3.15 (m, 2H), 2.6 (m, 6H), 2.45 (m, 2H), 1.9 (m, 2H), 1.65 (m, 2H), 1.25 (s, 9H), 0.9 (m, 3H)

EXAMPLE 4:

15 2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-propyl-pyrimidine hydrochloride

Reaction of 1 g of 2-tert-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-propyl-pyrimidine (2.95 mmol) with 0.42 g of 4-methyl-5-methyl-4H-[1,2,4]triazole-3-thiol (3.25 mmol) yielded 0.5 g (33.6 %) of title compound as a solid.

20 MS (ESI) m/z: 432.2 [M+H]⁺

¹H-NMR (DMSO): δ [ppm] 14.4 (s, 1H, broad), 12.1 (s, 1H, broad), 7.15 (s, 1H), 5.0 (m, broad, 1H), 4.5 (s, broad, 1H), 3.75 (m, 1H), 3.7 (m, broad, 3H), 3.65 (s, 3H), 3.4 (m, 2H), 3.3 (m, 2H), 3.25 (m, broad, 2H), 2.95 (m, 2H), 2.65 (s, 3H), 2.2 (m, 2H), 1.7 (m, 2H), 1.4 (s, 9H), 0.9 (m, 3H)

25 EXAMPLE 5:

2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine hydrochloride

3 g of 4-methyl-5-methyl-4H-[1,2,4]triazole-3-thiol (23.22 mmol) were reacted with 8.47 g of 2-tert-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-trifluoromethyl-pyrimidine (23.22 mmol) to yield 8.7 g of the title compound.

30

MS (ESI) m/z : 458.4 $[M+H]^+$

$^1\text{H-NMR}$ (DMSO): δ [ppm] 11.9 (s, 1H, broad), 7.2 (s, 1H), 4.7 (m, 2H), 3.5-3.8 (m, 7H), 3.4 (m, 2H), 3.2 (m, 2H), 3.1 (m, 2H), 2.6 (s, 3H), 2.2 (m, 2H), 1.3 (s, 9H)

EXAMPLE 6:

5 2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine hydrochloride

1 g of 4-methyl-4H-[1,2,4]triazole-3-thiol (8.7 mmol) were reacted with 3.2 g of 2-*tert*-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-trifluoromethyl-pyrimidine (8.7 mmol) to yield 2.1 g of the title compound as a solid.

10 Melting point: 92-95°C

MS (ESI) m/z : 444 $[M+H]^+$

$^1\text{H-NMR}$ (CDCl_3): δ [ppm] 8.15 (s, 1H), 6.6 (s, 1H), 3.75 (m, broad, 4), 3.6 (s, 3H), 2.55 (m, 6H), 2.0 (m, 2H), 1.35 (s, 9H)

EXAMPLE 7:

15 2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine hydrochloride

0.33 g of 4-methyl-4H-[1,2,4]triazole-3-thiol (2.88 mmol) were reacted with 1 g of 2-*tert*-Butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-difluoromethyl-pyrimidine (2.88 mmol) to yield 0.444 g of the product as a white solid.

20 MS (ESI) m/z : 426.4 $[M+H]^+$

$^1\text{H-NMR}$ (DMSO): δ [ppm] 11.9 (s, broad, 1H), 9.6 (s, 1H), 7.65 (s, broad, 4H), 7.05 (s, 1H), 6.8 (t, 1H, CHF₂), 4.65 (m, broad, 2H), 3.75 (s, 3H), 3.6 (m, broad, 4H), 3.4 (m, 2H), 3.25 (m, 2H), 3.1 (m, 2H), 2.2 (m, 2H), 1.3 (s, 9H).

EXAMPLE 8

25 2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine hydrochloride

0.5 g of 4-methyl-5-methyl-4H-[1,2,4]triazole-3-thiol (3.87 mmol) were reacted with 1.34 g of 2-*tert*-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-difluoromethyl-pyrimidine (3.87 mmol) to yield 0.58 g of the title compound.

MS (ESI) m/z : 440.2 $[M+H]^+$

$^1\text{H-NMR}$ (DMSO): δ [ppm] 11.8 (s, 1H, broad), 7.0 (s, 1H), 6.7 (t, 1H, CHF₂), 4.5-4.8 (m, 2H), 3.35-3.6 (m, 6H, broad), 3.35 (m, 2H), 3.2 (m, 2H), 3.05 (m, 2H, broad), 2.6 (s, 3H), 2.2 (m, 2H), 1.3 (m, 10H)

- 5 Following the same synthetic procedures, the following compounds of formula I, wherein R^1 , R^2 , and X have the meanings given in lines 9 to 12 of table 1, can be synthesized:

Table 1:

Example #	R^1	R^2
9	H	CH ₂ CF ₃
10	methyl	CH ₂ CF ₃
11	H	isopropyl
12	methyl	isopropyl

- 10 III. Preparation of Salts of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}- pyrimidine
1. Preparation of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}- pyrimidine Phosphoric Acid Salt (1:2 molar ratio)

15 To a stirred solution of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}- pyrimidine (1.0 g, 2.2 mmol) in 1 mL ethanol was added 85 % phosphoric acid (0.52 g, 4.4 mmol) in 1 mL ethanol. The mixture was heated to 70 °C to give a clear solution. 20 mL of ethyl acetate was slowly added at this temperature, and the mixture was slowly cooled to ambient temperature and stirred for additional two hours. The precipitate was filtered, rinsed with 5 mL ethyl acetate and vacuum dried at 45 °C to give the desired salt at 1:2 molar ratio of the

20 free base to phosphoric acid.

$^1\text{H NMR}$ (400 MHz, DMSO- d_6) δ 1.24 (s, 9H), 1.27 (s, 9H), 1.87-1.94 (m, 2H), 2.34 (s, 3H), 2.64-2.70 (m, 6H), 3.10 (t, 2H), 3.45 (s, 3H), 3.69 (br s, 4H), 6.50 (s, 1H), 10.28 (br s, 6H).

25 Elemental analysis for C₂₃H₄₅N₇O₈P₂S:
Calculated.: C, 43.05; H, 7.07; N, 15.28; P, 9.65; S, 5.00;

Found: C, 42.67; H, 6.95; N, 15.10; P, 9.42; S, 4.42.

2. Preparation of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine Phosphoric Acid Salt (1:4 molar ratio)

5 To a stirred solution of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine (7.47 g, 16.8 mmol) in isopropanol (74.70 g) was added a H₃PO₄ solution in water (8.23 g H₃PO₄ (85 %) in 28.89 g of water). The solution was heated to 60 °C and seeded with a slurry of the tetra-phosphate salt (143 mg) in isopropanol (1.41 g). The mixture was slowly cooled to
10 20 °C and isopropyl acetate (103.99 g) was charged. The solid was filtered off and washed (2 x 28 g) with a solution of isopropanol/isopropyl acetate (1:1). The solid was dried in a vacuum oven at 72 °C to afford 13.1 g (96.3 % yield) of 2,4-di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine tetra-phosphate salt as a white solid.

15

¹H NMR (400 MHz, DMSO-*d*₆) δ 1.25 (s, 9H), 1.29 (s, 9H), 2.01-2.15 (m, 2H), 2.36 (s, 3H), 3.06-3.24 (m, 8H) 3.48 (br s, 3H), 3.90 (s, 4H), 6.59 (s, 1H), 10.46 (s, 12H);
¹³C NMR (100 MHz, DMSO-*d*₆) δ 10.79, 24.00, 29.36, 29.60, 30.13, 30.21, 37.30, 40.78, 50.65, 54.40, 94.56, 147.93, 152.59, 161.27, 173.49, 175.21;

20

Elemental analysis for C₂₃H₅₁N₇O₁₆P₄S:

Calculated.: C, 32.98; H, 6.14; N, 11.71; P, 14.79; S, 3.83;

Found: C, 33.21; H, 6.21; N, 11.50; P, 13.97; S, 3.83.

3. Preparation of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine Sulfuric Acid Salt (1:1 molar ratio)

25

2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine (1.0 g, 2.2 mmol) was dissolved in isopropanol at 60 °C. A solution of concentrated sulfuric acid (0.22 g, 98 %, 2.2 mmol) in isopropanol (1 mL) was added giving a clear solution. Ethyl acetate (20 mL) was slowly added keeping the flask at ~50 °C. The resulting slurry was cooled to ambient temperature and stirred
30 overnight. The precipitate was filtered, rinsed with 10 mL ethyl acetate and vacuum dried at 40 °C overnight to give 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine mono-sulfate salt (1.06 g). Yield: 86.9 %.

Elemental analysis for $C_{23}H_{41}N_7O_4S_2$:

Calculated.: C, 50.80; H, 7.60; N, 18.03; S, 11.79;

Found: C, 50.97; H, 7.81; N, 18.23; S, 12.08.

- 5 4. Preparation of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine Benzenesulfonic Acid Salt (1:1 molar ratio)

10 A mixture of 2,4-di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine (0.63 g, 1.4 mmol), benzenesulfonic acid (0.25 g, 1.4 mmol) in ethyl acetate (5 mL) was warmed to 60 °C, and heptane (5 mL) was added. The resulting slurry was cooled to ambient temperature and stirred overnight. The precipitate was filtered, rinsed with ethyl acetate/heptane (1:1) and vacuum dried at 45 °C to give white crystals (0.80 g). Yield: 90.9 %.

15 1H NMR (CD_3OD , δ) 1.32 (s, 9H), 1.35 (s, 9H), 2.15-2.22 (m, 2H), 2.43 (s, 3H), 3.20-3.24 (m, 4H), 3.29-3.32 (m, 8H), 3.56 (s, 3H), 6.60 (s, 1H), 7.37-7.43 (m, 3H), 7.77-7.82 (m, 2H).

- 20 5. General Procedure for the Preparation of Other Acid Salts of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine including but not limited to mono acid salts such as fumaric acid, maleic acid, p-tosic acid, S-(+)-10-camphorsulfonic acid, glycolic acid, oxalic acid, mucic acid, nitric acid, trans-cinnamic acid, 2-furoic acid; bis salts such as maleic acid, p-tosic acid, benzenesulfonic acid, S-(+)-10-camphorsulfonic acid, nitric acid, methanesulfonic acid, malonic acid and oxalic acid; and tris salts such as nitric acid.

25 A mixture of 2,4-Di-tert-butyl-6-{4-[3-(4,5-dimethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine and respective acid (1 or 2 eq) is dissolved in 5 mL of alcoholic solvent (MeOH, EtOH, or isopropanol) per gram of free base. Heating is applied to dissolve the solids if necessary. Anti-solvent such as ethyl acetate, heptane or methyl t-butyl ether are added to precipitate the salt. The slurry is then cooled to < 20 °C and more anti-solvent is added until the concentration of the product in the mother liquor drops below 10 mg/mL. The precipitate is filtered, rinsed with the same solvents used to form the salt, and vacuum-dried to afford the corresponding acid salt. The stoichiometry of the acid in the salt is determined by either the potency assay or elemental analysis.

30

IV. Examples of galenic administration forms

A) Tablets

Tablets of the following composition are pressed on a tablet press in the customary manner:

40 mg of substance from Example 8
120 mg of corn starch
13.5 mg of gelatin
45 mg of lactose
2.25 mg of Aerosil® (chemically pure silicic acid in submicroscopically fine dispersion)
6.75 mg of potato starch (as a 6% paste)

B) Sugar-coated tablets

20 mg of substance from Example 8
60 mg of core composition
70 mg of saccharification composition

The core composition consists of 9 parts of corn starch, 3 parts of lactose and 1 part of 60:40 vinylpyrrolidone/vinyl acetate copolymer. The saccharification composition consists of 5 parts of cane sugar, 2 parts of corn starch, 2 parts of calcium carbonate and 1 part of talc. The sugar-coated tablets which had been prepared in this way are subsequently provided with a gastric juice-resistant coating.

V. Biological investigations

1. Receptor binding studies:

The substance to be tested was either dissolved in methanol/Chremophor® (BASF-AG) or in dimethyl sulfoxide and then diluted with water to the desired concentration.

Dopamine D₃ receptor:

The assay mixture (0.250 ml) was composed of membranes derived from ~ 10⁶ HEK-293 cells possessing stably expressed human dopamine D₃ receptors, 0.1 nM [¹²⁵I]-iodosulpride and incubation buffer (total binding) or, in addition, test substance

(inhibition curve) or 1 μ M spiperone (nonspecific binding). Each assay mixture was run in triplicate.

The incubation buffer contained 50 mM tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 2 mM MgCl_2 and 0.1% bovine serum albumin, 10 μ M quinolone and 0.1% ascorbic acid (prepared fresh daily). The buffer was adjusted to pH 7.4 with HCl.

Dopamine $\text{D}_{2\text{L}}$ receptor:

The assay mixture (1 ml) was composed of membranes from $\sim 10^6$ HEK-293 cells possessing stably expressed human dopamine $\text{D}_{2\text{L}}$ receptors (long isoform) and 0.01 nM [^{125}I] iodospiperone and incubation buffer (total binding) or, in addition, test substance (inhibition curve) or 1 μ M haloperidol (nonspecific binding). Each assay mixture was run in triplicate.

The incubation buffer contained 50 mM tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 2 mM MgCl_2 and 0.1% bovine serum albumin. The buffer was adjusted to pH 7.4 with HCl.

Measurement and analysis:

After having been incubated at 25°C for 60 minutes, the assay mixtures were filtered through a Wathman GF/B glass fiber filter under vacuum using a cell collecting device. The filters were transferred to scintillation vials using a filter transfer system. After 4 ml of Ultima Gold® (Packard) have been added, the samples were shaken for one hour and the radioactivity was then counted in a Beta-Counter (Packard, Tricarb 2000 or 2200CA). The cpm values were converted into dpm using a standard quench series and the program belonging to the instrument.

The inhibition curves were analyzed by means of iterative nonlinear regression analysis using the Statistical Analysis System (SAS) which is similar to the "LIGAND" program described by Munson and Rodbard.

In these tests, the compounds according to the invention exhibit very good affinities for the D_3 receptor ($K_i < 10$ nM, frequently < 5 nM) and bind selectively to the D_3 receptor.

The results of the binding tests are given in table 2, along with results obtained using two reference compounds A and B deemed representative of previously-described triazole compounds. The relative D_3 and D_2 affinities demonstrate the high selectivity of the compounds of the invention for the D_3 receptor.

2. Determination of the Concentration of compounds in Plasma and Brain Following Dosing of compounds in animals

Male Sprague-Dawley rats were used in this study (2 to 4 per experiment). The animals were fasted overnight prior to dosing and throughout the duration of the study but were permitted water *ad libitum*.

Each rat received a 10 mg/kg (5 mL/kg) dose orally by gavage. At 0.5, 3 and 8 hours after drug administration, three animals were put under deep anesthesia using isoflurane and euthanized by bleeding (cardiac puncture) under deep isoflurane anesthesia. EDTA blood samples and brain tissue will be collected from each rat. Upon collection, the samples were promptly placed in an ice bath, and within 2 hours after sample collection, the blood was centrifuged at about 4°C. The resulting brain and plasma samples were placed in clean glass tubes and stored in a freezer until analysis.

The plasma samples were assayed for parent compound using appropriate liquid chromatography – mass spectrometry procedures. The results are given in table 2 along with results obtained using the two reference compounds A and B, and illustrate the high brain concentrations attainable with the compounds of the invention.

Table 2:


Ex. #	R ¹	R ²	K _i D ₃ [nM]	K _i D ₂ [nM]	Selectivity [K _i (D ₂)/K _i (D ₃)]	Brain level [ng/g]
1	Methyl	<i>tert</i> -butyl	1.1	176	160	559
2	H	<i>tert</i> -butyl	1.7	127	75	1835
3	H	<i>n</i> -propyl	3.3	412	125	1000
4	Methyl	<i>n</i> -propyl	2.6	216	83	483
5	Methyl	CF ₃	3.7	311	84	904
6	H	CF ₃	3.5	469	134	2384
7	H	CHF ₂	2.9	418	146	1430
8	Methyl	CHF ₂	1.8	401	224	n.d.
A*	NH ₂	<i>tert</i> -butyl	0.7	12	19	387
B*	NH ₂	CF ₃	3.9	119	31	143

n.d. = not determined

* comparative examples

We claim:

1. Triazole compounds of the formula I



wherein

- 5 R^1 is selected from the group consisting of hydrogen and methyl; and
 R^2 is selected from the group consisting of C_3 - C_4 alkyl and C_1 - C_2 fluoroalkyl;
 and the physiologically tolerated acid addition salts of these compounds.
2. A compound as claimed in Claim 1, wherein R^1 is methyl.
3. A compound as claimed in Claim 1, wherein R^1 is hydrogen.
- 10 4. A compound as claimed in Claim 1, wherein R^2 is tert-butyl.
5. A compound as claimed in Claim 4, wherein R^1 is methyl.
6. A compound as claimed in Claim 4, wherein R^1 is hydrogen.
7. A compound as claimed in Claim 1, wherein R^2 is trifluoromethyl.
8. A compound as claimed in Claim 7, wherein R^1 is methyl.
- 15 9. A compound as claimed in Claim 7, wherein R^1 is hydrogen.
10. A compound as claimed in Claim 1, wherein R^2 is *n*-propyl.
11. A compound as claimed in Claim 10, wherein R^1 is methyl.
12. A compound as claimed in Claim 10, wherein R^1 is hydrogen.
13. A compound as claimed in Claim 1, selected from the group consisting of
 20 2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-*tert*-butyl-pyrimidine,
 2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-

trifluoromethyl-pyrimidine,

2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine and

2-*tert*-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-*tert*-butyl-pyrimidine,

2-*tert*-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine.

and the physiologically tolerated acid addition salts of these compounds.

- 5
- 10
14. A pharmaceutical composition comprising at least one compound as claimed in Claim 1 together with at least one physiologically acceptable carrier or auxiliary substance.
15. A method for treating a medical disorder of the central nervous system susceptible to treatment with a dopamine D₃ receptor antagonist or a dopamine D₃ agonist, said method comprising administering an effective amount of at least one compound as claimed in Claim 1 to a subject in need thereof.
- 15
16. The method as claimed in Claim 15, wherein the medical disorder is schizophrenia.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 2004/006139

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D403/12 A61K31/506 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96/02520 A (BASF AG ; UNGER LILIANE (DE); WICKE KARSTEN (DE); DRESCHER KARLA (DE);) 1 February 1996 (1996-02-01) cited in the application page 20; compounds 40,44 -----	1-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

15 September 2004

Date of mailing of the international search report

22/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Grassi, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC19/2004/006139

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9602520 A	01-02-1996	DE 4425144 A1	18-01-1996
		WO 9602520 A1	01-02-1996
		AU 703889 B2	01-04-1999
		AU 3111395 A	16-02-1996
		BG 63500 B1	29-03-2002
		BG 101113 A	30-04-1998
		BR 9508294 A	30-12-1997
		CZ 9700097 A3	13-08-1997
		DE 59505853 D1	10-06-1999
		DK 772604 T3	01-11-1999
		EP 0772604 A1	14-05-1997
		FI 970147 A	14-01-1997
		GR 3030371 T3	30-09-1999
		JP 10502914 T	17-03-1998
		NO 970161 A	14-03-1997
		NZ 290387 A	25-02-1999
		SI 9520083 A	31-10-1997
		US 6403593 B1	11-06-2002
		US 6124294 A	26-09-2000
		AT 179703 T	15-05-1999
		CA 2195243 A1	01-02-1996
		CN 1152919 A ,B	25-06-1997
		ES 2131842 T3	01-08-1999
		HU 77128 A2	02-03-1998
		IL 114598 A	22-12-1999
		RU 2167869 C2	27-05-2001
		ZA 9505867 A	14-01-1997